These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 24486136

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Mycophenolic acid glucuronide is transported by multidrug resistance-associated protein 2 and this transport is not inhibited by cyclosporine, tacrolimus or sirolimus.
    Patel CG, Ogasawara K, Akhlaghi F.
    Xenobiotica; 2013 Mar; 43(3):229-35. PubMed ID: 22934787
    [Abstract] [Full Text] [Related]

  • 5. Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: implications for drug exposure in renal allograft recipients.
    Naesens M, Kuypers DR, Streit F, Armstrong VW, Oellerich M, Verbeke K, Vanrenterghem Y.
    Clin Pharmacol Ther; 2006 Nov; 80(5):509-21. PubMed ID: 17112807
    [Abstract] [Full Text] [Related]

  • 6. Role of Mrp2 in the hepatic disposition of mycophenolic acid and its glucuronide metabolites: effect of cyclosporine.
    Westley IS, Brogan LR, Morris RG, Evans AM, Sallustio BC.
    Drug Metab Dispos; 2006 Feb; 34(2):261-6. PubMed ID: 16272406
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The impact of P-glycoprotein and Mrp2 on mycophenolic acid levels in mice.
    Wang J, Figurski M, Shaw LM, Burckart GJ.
    Transpl Immunol; 2008 Jul; 19(3-4):192-6. PubMed ID: 18586494
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics of mycophenolic acid and its phenolic-glucuronide and ACYl glucuronide metabolites in stable thoracic transplant recipients.
    Ting LS, Partovi N, Levy RD, Riggs KW, Ensom MH.
    Ther Drug Monit; 2008 Jun; 30(3):282-91. PubMed ID: 18520599
    [Abstract] [Full Text] [Related]

  • 10. MRP4 is responsible for the efflux transport of mycophenolic acid β-d glucuronide (MPAG) from hepatocytes to blood.
    Berthier J, Benmameri M, Sauvage FL, Fabre G, Chantemargue B, Arnion H, Marquet P, Trouillas P, Picard N, Saint-Marcoux F.
    Xenobiotica; 2021 Jan; 51(1):105-114. PubMed ID: 32820679
    [Abstract] [Full Text] [Related]

  • 11. Effects of calcineurin inhibitors on pharmacokinetics of mycophenolic acid and its glucuronide metabolite during the maintenance period following renal transplantation.
    Naito T, Shinno K, Maeda T, Kagawa Y, Hashimoto H, Otsuka A, Takayama T, Ushiyama T, Suzuki K, Ozono S.
    Biol Pharm Bull; 2006 Feb; 29(2):275-80. PubMed ID: 16462031
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Steady-state pharmacokinetics of mycophenolic acid in renal transplant patients: exploratory analysis of the effects of cyclosporine, recipients' and donors' ABCC2 gene variants, and their interactions.
    Božina N, Lalić Z, Nađ-Škegro S, Borić-Bilušić A, Božina T, Kaštelan Ž, Trkulja V.
    Eur J Clin Pharmacol; 2017 Sep; 73(9):1129-1140. PubMed ID: 28624888
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetic modeling of enterohepatic circulation of mycophenolic acid in renal transplant recipients.
    Colom H, Lloberas N, Andreu F, Caldés A, Torras J, Oppenheimer F, Sanchez-Plumed J, Gentil MA, Kuypers DR, Brunet M, Ekberg H, Grinyó JM.
    Kidney Int; 2014 Jun; 85(6):1434-43. PubMed ID: 24402086
    [Abstract] [Full Text] [Related]

  • 15. Difference between pharmacokinetics of mycophenolic acid (MPA) in rats and that in humans is caused by different affinities of MRP2 to a glucuronized form.
    Takekuma Y, Kakiuchi H, Yamazaki K, Miyauchi S, Kikukawa T, Kamo N, Ganapathy V, Sugawara M.
    J Pharm Pharm Sci; 2007 Jun; 10(1):71-85. PubMed ID: 17498396
    [Abstract] [Full Text] [Related]

  • 16. Impact of calcineurin inhibitors on urinary excretion of mycophenolic acid and its glucuronide in kidney transplant recipients.
    Naito T, Mino Y, Otsuka A, Ushiyama T, Ito T, Ozono S, Kagawa Y, Kawakami J.
    J Clin Pharmacol; 2009 Jun; 49(6):710-8. PubMed ID: 19451405
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effects of poloxamer 407-induced hyperlipidemia on hepatic multidrug resistance protein 2 (Mrp2/Abcc2) and the pharmacokinetics of mycophenolic acid in rats.
    Kwon MH, Yoon JN, Baek YJ, Kim YC, Cho YY, Kang HE.
    Biopharm Drug Dispos; 2016 Sep; 37(6):352-65. PubMed ID: 27241939
    [Abstract] [Full Text] [Related]

  • 19. Can xipamide or tacrolimus inhibit the glucuronidation of mycophenolic acid in rat liver slices?
    Balogh A, Merkel U, Müller D.
    Exp Toxicol Pathol; 2003 Jun; 54(5-6):375-9. PubMed ID: 12877348
    [Abstract] [Full Text] [Related]

  • 20. In vivo higher glucuronidation of mycophenolic acid in male than in female recipients of a cadaveric kidney allograft and under immunosuppressive therapy with mycophenolate mofetil.
    Morissette P, Albert C, Busque S, St-Louis G, Vinet B.
    Ther Drug Monit; 2001 Oct; 23(5):520-5. PubMed ID: 11591897
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.